Donated globally since 2005, Novartis' flatworm treatment Egaten wins FDA nod — and a PRV
Novartis $NVS has the fix for all your parasitic flatworm needs. The Swiss drugmaker developed a human treatment for fascioliasis in partnership with the WHO after formulating a similar medicine for domestic livestock who are also vulnerable to the neglected tropical disease, which has cropped up in more than 70 countries. Since 2005, the drugmaker has been donating the drug — Egaten — globally, and on Wednesday, the medicine was approved by the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.